Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
NCT06397027Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib in acute leukemia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT06397027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397027.